Lunit to Collaborate With 10x Genomics on Precision Medicine Biomarker Discovery
TECHWORLD ·
✦ AI Summary
Lunit announced on the 11th that it will collaborate with 10x Genomics on precision medicine biomarker discovery.
The collaboration will combine 10x Genomics' spatial biology-based gene analysis with Lunit's AI pathology analysis.
The two companies plan to analyze molecular data and pathology images together in tumor research to identify biomarkers that can predict response to cancer treatments.
Lunit is collaborating with 10x Genomics to discover precision medicine biomarkers. Lunit announced the partnership on the 11th. The purpose of the collaboration is to identify biomarkers that can predict cancer treatment response.
The collaboration will combine 10x Genomics' spatial biology-based gene analysis with Lunit's AI pathology analysis. The goal is to identify biomarkers that can predict the effectiveness of cancer drug treatments.
To that end, 10x Genomics will apply Lunit AI biomarker platform, "Lunit SCOPE IO," to its tumor research. It will jointly analyze molecular data and pathology images obtained from the same tumor tissue to identify features associated with treatment response.
10x Genomics is a Nasdaq-listed global life sciences company founded in 2012 that has developed spatial biology technology. Spatial biology is a technology for analyzing the location of gene expression by cell within tissue, as well as the interactions between cells. Research papers that have used 10x Genomics' technology have exceeded 10,000.
10x Genomics uses its spatial analysis platforms, "GEM-X" and "Atera," to analyze gene expression by cell within tissue. The function of "GEM-X" and "Atera" is to analyze gene expression by cell within tissue.
Lunit performs analyses based on H&E-stained tissue slides. Its analysis quantifies the distribution and structure of cancer cells and immune cells, with the aim of analyzing the tumor microenvironment. Lunit SCOPE IO is an AI biomarker platform based on H&E-stained tissue images. Its functions are quantitative analysis of the tumor microenvironment (TME) and classification of patient immune phenotypes (IP), and it has been used in biomarker research related to immunotherapy response across multiple cancer types.
The two companies plan to connect the results of the two analyses. The integration under review is the correspondence between molecular-level tumor characteristics and morphological patterns in pathology images.
Based on the integrated results, the companies plan to develop biomarkers for identifying patients likely to respond to drugs. The initial research targets are antibody-drug conjugates (ADC) and immuno-oncology drugs, and the research goal is to identify molecular and pathological features associated with responses to each therapy. The companies plan to use this in research on predicting treatment response.
Lunit emphasized the significance of 10x Genomics, which has led the spatial biology field in the global market, choosing Lunit's technology for its own tumor research. Lunit CEO Seo Beom-seok said that Lunit SCOPE IO is being used in research at a world-class global research site and expressed his intention to pursue the discovery of new biomarkers that connect molecular information with pathology images based on that work.
10x Genomics said that combining molecular data with AI analysis could deepen researchers' understanding of tumors. Roman Jlenski, vice president of clinical applications at 10x Genomics, said he expects this combination to accelerate the discovery of biomarkers that can be used to establish treatment strategies.
Source: TECHWORLD · Kim Seung-gi
Original: https://www.epnc.co.kr/news/articleView.html?idxno=406840
References
This article was produced with the help of an automated content generation algorithm.
Source: TECHWORLD
View originalThis article was summarized and organized by BizCrush based on the original article from TECHWORLD. For exact quotations and full details, please refer to the original article.